Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Phase 2/Phase 3
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Acute Myeloid Leukemia
Both
Acute Myeloid Leukemia
Trial Information
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Inclusion Criteria:
1. Age 18 years to 75 years
2. Able to give informed consent
3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2,
that has been treated with induction therapy in the last four weeks
4. ECOG performance status of 0 or 1 -
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Relapse free survival
Outcome Time Frame:
2 year
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
J1227
NCT ID:
NCT01588951
Start Date:
July 2012
Completion Date:
June 2017
Related Keywords:
- Acute Myeloid Leukemia
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland 21231-2410 |
